What is BOLT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BOLT?

P/E (TTM) is n/a and 52-week range is $3.10 to $7.20 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BOLT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BOLT?

The company profile lists revenue (TTM) near $5M, net income (TTM) near $-3.26B, EPS (TTM) near $-16.44 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Bolt Biotherapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Redwood City, California, US, 1.9M shares outstanding, ISIN US0977022039 when available from company profile and filing metadata.

Bolt Biotherapeutics Inc

$BOLT

Health Care · Biotechnology

IR Run Scenarios

$4.11

+12.60%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is headquartered in Redwood City, California and currently employs 23 full-time employees. The company went IPO on 2021-02-05. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The firm is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

Employees

Website

boltbio.com/

IPO

2021-02-05

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)